论文部分内容阅读
新西兰药物经济学评价指南由药品管理有限公司/卫生基金管理局负责制定,最早于1999年公布,属非正式指南,主要为医药管理机构开展药物经济学评价提供指导性意见。新西兰医药管理由医药管理机构于2004年对原版进行修订并于2007年完稿,现行版本为第2版,较之第1版内容更加完善、系统、详细;对当前国际上现有的药物经济学评价指南涉及到的有争议的热点问题给予了探讨。该文从新版指南与第1版区别、修订的内容、现行版本特点、与第1版相比进步之处以及未来修订工作方向等对新版新西兰药物经济学评价指南内容做了简单介绍,为我国制定相关指导性文件提供参考意见。
The New Zealand Pharmacoeconomics Evaluation Guide, which was drafted by the Pharmaceutical Administration Limited / Health Care Fund Administration and was first published in 1999, is an informal guideline that provides guidance for the pharmaceutical regulatory agencies in conducting pharmacoeconomic evaluations. New Zealand Pharmaceutical Administration The original version was revised by the medical regulatory body in 2004 and was finalized in 2007. The current version is the second version, which is more complete, systematic and detailed than the first version. The current international pharmacoeconomics The controversial hot issues involved in the evaluation guidelines were explored. This article makes a brief introduction of the contents of the New Zealand Guide to Evaluation of Pharmacoeconomics from the difference between the new version and the first edition, the content of the revision, the characteristics of the current version, the progress compared with the first edition and the direction of future revision. Development of relevant guidance documents provide reference.